The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update

The Keap1-Nrf2-ARE ((Kelch-like ECH-Associating protein 1) nuclear factor erythroid 2 related factor 2-antioxidant response element) pathway is one of the most important defense mechanisms against oxidative and/or electrophilic stresses, and it is closely associated with inflammatory diseases, including cancer, neurodegenerative diseases, cardiovascular diseases, and aging. In recent years, progress has been made in strategies aimed at modulating the Keap1-Nrf2-ARE pathway. The Nrf2 activator DMF (Dimethylfumarates) has been approved by the FDA as a new first-line oral drug to treat patients with relapsing forms of multiple sclerosis, while a phase 3 study of another promising candidate, CDDO-Me, was…

• NN
  National Natural Science Foundation of China

  Award: 2014ZX09507002‐005‐015, 2013ZX09402102‐001‐005, 2010ZX09401‐401
• CP
  China Pharmaceutical University

  Awards: 210009, SKLNMZZCX201611